(Updates with further details and background)
March 20 (Reuters) - Australian Clinical Labs (ACL) said on Monday it will acquire Healius (HLS) through an all-share takeover, valuing the medical center operator at A$1.52 billion ($1.02 billion).
The pathology firm said it will offer 0.74 share for every Healius share. The offer price represents a discount of about 4.2% to Healius' last close.
If the deal is successful, Healius' shareholder will own 68% of the merged entity, the company said in a statement.
In 2020, Healius rejected a $1.3 billion buyout offer from Partners Group, saying at the time it undervalued the medical center operator.
($1 = 1.4896 Australian dollars)
News: HLS UPDATE 1-Australian Clinical Labs offers to buy Healius for $1 billion
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
81.5¢ |
Change
-0.020(2.40%) |
Mkt cap ! $591.7M | |||
| Open | High | Low | Value | Volume |
| 81.0¢ | 83.0¢ | 78.0¢ | $4.121M | 5.071M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 75365 | 81.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 84.5¢ | 5500 | 1 |
View Market Depth
| Last trade - 16.10pm 12/08/2025 (20 minute delay) ? |
| HLS (ASX) Chart |